Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether docetaxel and carboplatin are more effective with or without trastuzumab in treating breast cancer.
PURPOSE: This randomized phase II trial is studying how well giving docetaxel together with carboplatin and trastuzumab before surgery works compared to docetaxel and carboplatin alone before surgery in treating women with locally advanced breast cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
-
-
California
-
Los Angeles, California, United States, 90095-1781
- Jonsson Comprehensive Cancer Center at UCLA
-
Los Angeles, California, United States, 90089-9181
- USC/Norris Comprehensive Cancer Center and Hospital
-
Pomona, California, United States, 91767-3021
- Wilshire Oncology Medical Group, Incorporated - Pomona
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Confirmed infiltrating adenocarcinoma of the breast
- Primary breast cancer > 5cm, or skin/chest wall involvement, any N, without evidence of metastasis.
- No prior radiation to the involved breast
- ECOG (Electrocochleography) performance status 0-2
- Age 18 years to 80 years
- Absolute Neutrophil count > 1500 cell/μl, platelet count > 100000 cells/μl and hemoglobin > 9 g/dl
- All liver function tests < upper limit of normal
- Serum creatinine < 2.0 mg/dl
- Normal left ventricular ejection fraction (LVEF) as determined by MUGA (Multiple Gated Acquisition) scan or echocardiogram
- HER-2/neu status is determined by a FISH (Fluorescence in situ hybridization) test. [FISH (+) is HER-2/neu (+)]
- If female of childbearing potential, pregnancy test is negative
- If premenopausal and not surgically sterilized, the patient agrees to use effective birth control method for the duration of the study
- Informed consent has been obtained
Exclusion Criteria:
- Non-confirmed infiltrating adenocarcinoma breast cancer
- Evidence of metastasis
- Previous chemotherapy using the drugs proposed in this study, specifically Herceptin®, Taxotere®, and/or Carboplatin
- Prior radiation to the involved breast
- Recent breast cancer drug therapy within last 5 years of any form
- History of allergy to polysorbate or castor oil
- Ongoing active infection
- Concurrent life-limiting disease with a life expectancy of less than one year
- Past or current history of other malignancy within the past 5 years which could affect the diagnosis or assessment of breast cancer, except for curatively treated non-melanoma skin cancer and/or in situ carcinoma of the cervix
- Pregnancy, nursing, fertile women who do not use birth control device
- Inability to give informed consent
- Patients with pre-existing peripheral neuropathy > grade 2
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Arm I (neoadjuvant therapy)
see intervention description
|
Cycle 5-7 post-op only Day 1 4mg/kg IV Day 8, 15 2mg/kg IV Cycle 8 Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV
Other Names:
Cycle 1-8 Day 1 or 2 AUC = 6 IV
Cycle 1-8 Day 1 or 2: 75 mg/m2 IV
Other Names:
Cycle 1-4 pre-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV Cycle 5-7 post-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV
Other Names:
|
|
Experimental: Arm II (neoadjuvant therapy)
please see intervention description
|
Cycle 5-7 post-op only Day 1 4mg/kg IV Day 8, 15 2mg/kg IV Cycle 8 Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV
Other Names:
Cycle 1-8 Day 1 or 2 AUC = 6 IV
Cycle 1-8 Day 1 or 2: 75 mg/m2 IV
Other Names:
Cycle 1-4 pre-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV Cycle 5-7 post-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV
Other Names:
|
|
Experimental: HER2/neu negative patients
please see intervention description
|
Cycle 1-8 Day 1 or 2 AUC = 6 IV
Cycle 1-8 Day 1 or 2: 75 mg/m2 IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluate the Objective Response Rate of Patients Treated With Taxotere/Carboplatin With or Without Herceptin Preoperatively.
Time Frame: 5 years
|
Objective response rate of patients treated with Taxotere/carboplatin with or without Herceptin preoperatively. Objective response equals the combination of complete response (CR), partial response (PR) and marginal response (MR). Tumor size was assessed by (1) physical examination, (2) mammography and (3) MRI. 5 response groups: complete response (CR), partial response (PR), marginal response (MR), stable disease (SD) & disease progression (DP). Pathologic response assigned into 2 groups: pCR and non-pCR. pCR-no evidence of residual invasive disease in specimen. |
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Tumor Response by Physical Exam and Imaging Studies
Time Frame: 5 years
|
5 years
|
|
|
Tumor Response Assessment
Time Frame: 5 years
|
Measured by physical examination compared to breast mammography and MRI assessment
|
5 years
|
|
Clinico-histologic Predictors of pCR (Pathologic Complete Response)
Time Frame: 5 years
|
5 years
|
|
|
Pathologic Nodal Status
Time Frame: 5 years
|
According to Primary Tumor Response Pathologic lymph node status N0 Axillary and other nearby lymph nodes do not have cancer (when looked at under a microscope) N1 Micrometastases (very small clusters of cancer) OR 1-3 axillary lymph nodes have cancer AND/OR Internal mammary nodes have tiny amounts of cancer found on sentinel node biopsy N2 4-9 axillary lymph nodes have cancer OR Internal mammary nodes have cancer, but axillary lymph nodes do not have cancer N3 10 or more axillary lymph nodes have cancer OR Infraclavicular (under the clavicle) nodes have cancer OR Internal mammary nodes have cancer plus 1 or more axillary lymph nodes have cancer OR 4 or more axillary lymph nodes have cancer plus internal mammary nodes have cancer or micrometastases found on sentinel node biopsy OR Supraclavicular (above the clavicle) nodes have cancer
|
5 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Helena R. Chang, MD, PhD, Jonsson Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 99-11-084
- CDR0000321924
- AVENTIS-GIA-11156
- GENENTECH-H2269s
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.